Cofactor-Independent Phosphoglycerate Mutase from Nematodes Has Limited Druggability, as Revealed by Two High-Throughput Screens

PLoS Neglected Tropical Diseases

Volumn 8, Issue 1, 2014, Pages 34-

  Crowther, Gregory J ^a   Booker, Michael L ^b   He, Min ^c   Li, Ting ^c   Raverdy, Sylvine ^d   Novelli, Jacopo F ^d   He, Panqing ^a   Dale, Natalie R G ^a   Fife, Amy M ^b   Barker Jr , Robert H ^b   Kramer, Martin L ^b   Van Voorhis, Wesley C ^a   Carlow, Clotilde K S ^d   Wang, Ming Wei ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GENZYME CORPORATION   (United States)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^d NEW ENGLAND BIOLABS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1, 10 PHENANTHROLINE; COFACTOR INDEPENDENT PHOSPHOGLYCERATE MUTASE; PHOSPHOGLYCERATE MUTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TANNIN; UNCLASSIFIED DRUG; ANTIFILARIAL AGENT; ENZYME INHIBITOR;

ARTICLE; BRUGIA MALAYI; CAENORHABDITIS ELEGANS; CATALYSIS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; NONHUMAN; NUCLEOTIDE SEQUENCE; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; IC 50; ISOLATION AND PURIFICATION;

ANIMALS; BRUGIA MALAYI; ENZYME INHIBITORS; FILARICIDES; HIGH-THROUGHPUT SCREENING ASSAYS; INHIBITORY CONCENTRATION 50; PHOSPHOGLYCERATE MUTASE;

EID: 84893807769     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002628     Document Type: Article

References (40)

1. Brown D, Superti-Furga G, (2003) Rediscovering the sweet spot in drug discovery. Drug Discov Today 8: 1067-1077.
2. Hopkins AL, Bickerton GR, Carruthers IM, Boyer SK, Rubin H, et al. (2011) Rapid analysis of pharmacology for infectious diseases. Curr Top Med Chem 11: 1292-1300.
3. Adams JC, Keiser MJ, Basuino L, Chambers HF, Lee DS, et al. (2009) A mapping of drug space from the viewpoint of small molecule metabolism. PLoS Comput Biol 5: e1000474.
4. Dobson PD, Patel Y, Kell DB, (2009) 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. Drug Discov Today 14: 31-40.
5. Lustigman S, Prichard RK, Gazzinelli A, Grant WN, Boatin BA, et al. (2012) A research agenda for helminth diseases of humans: the problem of helminthiases. PLoS Negl Trop Dis 6: e1582.
6. Hoerauf A, Pfarr K, Mand S, Debrah AY, Specht S, (2011) Filariasis in Africa-treatment challenges and prospects. Clin Microbiol Infect 17: 977-985.
7. Zhang Y, Foster JM, Kumar S, Fougere M, Carlow CK, (2004) Cofactor-independent phosphoglycerate mutase has an essential role in Caenorhabditis elegans and is conserved in parasitic nematodes. J Biol Chem 279: 37185-37190.
8. Raverdy S, Zhang Y, Foster J, Carlow CK, (2007) Molecular and biochemical characterization of nematode cofactor independent phosphoglycerate mutases. Mol Biochem Parasitol 156: 210-216.
9. Jedrzejas MJ, (2000) Structure, function, and evolution of phosphoglycerate mutases: comparison with fructose-2,6-bisphosphatase, acid phosphatase, and alkaline phosphatase. Prog Biophys Mol Biol 73: 263-287.
10. Jedrzejas MJ, Chander M, Setlow P, Krishnasamy G, (2000) Mechanism of catalysis of the cofactor-independent phosphoglycerate mutase from Bacillus stearothermophilus. Crystal structure of the complex with 2-phosphoglycerate. J Biol Chem 275: 23146-23153.
11. Nukui M, Mello LV, Littlejohn JE, Setlow B, Setlow P, et al. (2007) Structure and molecular mechanism of Bacillus anthracis cofactor-independent phosphoglycerate mutase: a crucial enzyme for spores and growing cells of Bacillus species. Biophys J 92: 977-988.
12. Jedrzejas MJ, Chander M, Setlow P, Krishnasamy G, (2000) Structure and mechanism of action of a novel phosphoglycerate mutase from Bacillus stearothermophilus. Embo J 19: 1419-1431.
13. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
14. Swinney DC, (2004) Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 3: 801-808.
15. Spence RA, Kati WM, Anderson KS, Johnson KA, (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267: 988-993.
16. Al-Mawsawi LQ, Neamati N, (2011) Allosteric inhibitor development targeting HIV-1 integrase. ChemMedChem 6: 228-241.
17. Barreca ML, Iraci N, Manfroni G, Cecchetti V, (2011) Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. Future Med Chem 3: 1027-1055.
18. Laine E, Martinez L, Ladant D, Malliavin T, Blondel A, (2012) Molecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors. Toxins (Basel) 4: 580-604.
19. Jakobsen PH, Wang MW, Nwaka S, (2011) Innovative partnerships for drug discovery against neglected diseases. PLoS Negl Trop Dis 5: e1221.
20. Kumar A, Zhang M, Zhu L, Liao RP, Mutai C, et al. (2012) High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity. PLoS ONE 7: e39961.
21. Zhao H, (2007) Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug discovery today 12: 149-155.
22. Shakya S, Bajpai P, Sharma S, Misra-Bhattacharya S, (2008) Prior killing of intracellular bacteria Wolbachia reduces inflammatory reactions and improves antifilarial efficacy of diethylcarbamazine in rodent model of Brugia malayi. Parasitol Res 102: 963-972.
23. Mehlin C, Boni E, Buckner FS, Engel L, Feist T, et al. (2006) Heterologous expression of proteins from Plasmodium falciparum: Results from 1000 genes. Mol Biochem Parasitol 148: 144-160.
24. Congreve M, Carr R, Murray C, Jhoti H, (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8: 876-877.
25. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, et al. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-2623.
26. Seidler J, McGovern SL, Doman TN, Shoichet BK, (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. Journal of medicinal chemistry 46: 4477-4486.
27. Zhang JH, Chung TD, Oldenburg KR, (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73.
28. Patel V, Booker M, Kramer M, Ross L, Celatka CA, et al. (2008) Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 283: 35078-35085.
29. Rigden DJ, Lamani E, Mello LV, Littlejohn JE, Jedrzejas MJ, (2003) Insights into the catalytic mechanism of cofactor-independent phosphoglycerate mutase from X-ray crystallography, simulated dynamics and molecular modeling. J Mol Biol 328: 909-920.
30. Dessen A, Tang J, Schmidt H, Stahl M, Clark JD, et al. (1999) Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell 97: 349-360.
31. McKew JC, Foley MA, Thakker P, Behnke ML, Lovering FE, et al. (2006) Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization. J Med Chem 49: 135-158.
32. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, et al. (2009) Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 3: e440.
33. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2012) PubChem's BioAssay Database. Nucleic Acids Res 40: D400-412.
34. Djikeng A, Raverdy S, Foster J, Bartholomeu D, Zhang Y, et al. (2007) Cofactor-independent phosphoglycerate mutase is an essential gene in procyclic form Trypanosoma brucei. Parasitol Res 100: 887-892.
35. Mercaldi GF, Pereira HM, Cordeiro AT, Michels PA, Thiemann OH, (2012) Structural role of the active-site metal in the conformation of Trypanosoma brucei phosphoglycerate mutase. FEBS J 279: 2012-2021.
36. Sharma OP, Vadlamudi Y, Liao Q, Strodel B, Suresh Kumar M, (2012) Molecular modeling, dynamics, and an insight into the structural inhibition of cofactor independent phosphoglycerate mutase isoform 1 from Wuchereria bancrofti using cheminformatics and mutational studies. J Biomol Struct Dyn 31: 765-778.
37. Laurie AT, Jackson RM, (2005) Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21: 1908-1916.
38. Hardy JA, Wells JA, (2004) Searching for new allosteric sites in enzymes. Curr Opin Struct Biol 14: 706-715.
39. Gupta A, Gupta AK, Seshadri K, (2009) Structural models in the assessment of protein druggability based on HTS data. J Comput Aided Mol Des 23: 583-592.
40. Pohjala L, Tammela P, (2012) Aggregating behavior of phenolic compounds-a source of false bioassay results? Molecules 17: 10774-10790.